Advanced Non Small Cell Lung Cancer
25
6
10
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.0%
2 terminated out of 25 trials
84.6%
-1.9% vs benchmark
16%
4 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (25)
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
AZD9291 First Time In Patients Ascending Dose Study
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
Long-Term Follow-Up Study of Patients Receiving ATL001
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
D-0316 First Time in Patients Ascending Dose Study
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer